End Brain Cancer

What End Brain Cancer does

The End Brain Cancer Initiative (EBCI), formerly The Chris Elliott Fund, is a 501(c)(3) non-profit patient advocacy organization founded in May 2002 by Dellann Elliott Mydland and headquartered in Redmond, Washington. The organization addresses a specific gap in the brain cancer patient journey: the disconnect between initial diagnosis and immediate access to top-tier specialists, advanced treatments, and clinical trials. EBCI's core offering is the Direct Connect Program, a 5-step patient navigation service that handles over 7,000 inquiries per month and facilitates connections to neurosurgeons, neuro-oncologists, and clinical trial sites through a Medical Advisory Board drawn from institutions including Dana-Farber Cancer Institute, Duke University, and UCSF. All patient services are provided free of charge.

The organization's product portfolio centers on the EBCI Mobile App (launched November 2022), which provides 24/7 self-serve access to clinical trial information, patient resources, and educational materials on iOS and Android, alongside a Patient Resource Center, Caregiver Resource Center, Health Insurance Navigator, and Travel & Financial Resources service. EBCI runs recurring educational programming including bi-annual caregiver self-care webinars (sponsored by Novocure since 2007), annual "Know All Your Treatment Options" events, GBM Awareness Day, and the National HOPE Award. The organization maintains clinical trial partnerships with 15+ pharma/biotech sponsors including Deciphera, Servier, Imvax, Curis, IN8Bio, GT Medical, Kiyatec, Belay Diagnostics, Exvade Bioscience, and Pacific Marine Biotech, and strategic partnerships with the National Cancer Institute (NCI-CONNECT) and ASCO.

EBCI's business model is donation- and sponsorship-based: the organization is funded through individual donations, corporate sponsorships from biotech and pharma companies underwriting educational events, and fundraising activities (Gray Ribbon Gala, GiveBIG campaigns, golf tournaments, online bookstore with 100% proceeds to EBCI). As a non-equity non-profit, EBCI has no parent company, no institutional investors, and no traditional venture funding; governance is provided by a Board of Directors with Dellann Elliott Mydland as Founder/President/CEO. The organization actively advocates for the Promising Pathway Act (S.4426), which would create an FDA provisional approval pathway for rapid-progressing diseases with few treatment options. Revenue is not publicly disclosed.

Name

End Brain Cancer

Legal name

End Brain Cancer Initiative

Website

https://endbraincancer.org

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

1–10 employees

Short description

End Brain Cancer Initiative (EBCI) is a 501(c)(3) non-profit founded in 2002 that connects brain cancer patients and caregivers to specialists, clinical trials, and advanced treatments through its Direct Connect navigation program, mobile app, and educational resources, operating free of charge across the United States.

Ownership category

akta.pro rank

Product category

Patient Advocacy Services

NAICS

Other Individual and Family Services (624190)

SIC

Services-Health Services (8000)

akta.pro primary industry

Healthcare & Clinical Professional Development (CME/CE) (EDAGANAJ)

Keywords

• Patient advocacy services
• Clinical trial navigation
• Brain cancer education
• Patient navigation services
• Disease awareness advocacy

Headquarters

HQ city

Redmond

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Donations and Fundraising: As a 501(c)(3) non-profit organization, EBCI relies on donations from individuals, corporate sponsors, and fundraising events including golf tournaments, Gray Ribbon Gala, and GiveBIG campaigns.
2. Corporate Sponsorships: Corporate partners support the organization through educational/outreach meeting & event sponsorships. Partners include Deciphera, Novocure, Servier, Imvax, Belay Diagnostics, Curis, Exvade Bioscience, Pacific Marine Biotech, and others.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Core offering

End Brain Cancer Initiative (EBCI) is a 501(c)(3) non-profit patient advocacy organization that connects brain cancer patients and caregivers to specialists, advanced treatments, and clinical trials through its Direct Connect Program and EBCI mobile application. Services are provided free of charge and include patient navigation, health insurance advocacy, travel and financial resource coordination, caregiver support, and disease education via webinars, resource centers, and the EBCI App. EBCI also advocates for policy changes such as the Promising Pathway Act to expand treatment access.

Product overview

The End Brain Cancer Initiative (EBCI) is a 501(c)(3) non-profit patient advocacy organization offering a comprehensive suite of patient support services centered around its EBCI mobile application. The core offering includes the EBCI App, which serves as a unified platform providing clinical trial information, patient resources, research links, and educational materials. The organization complements its digital offerings with direct patient support through the Direct Connect Program (a 5-step patient navigation service), Health Insurance Navigator, and Travel & Financial Resources. Educational initiatives include patient and caregiver resource centers, fact sheets, webinars (Know All Your Treatment Options, National Caregivers Self-Care), and the National HOPE Award program. EBCI maintains active clinical trial partnerships with multiple biotechnology and medical device companies including Deciphera (Ignite Trial), Imvax, Curis (TakeAim), Belay Diagnostics, Exvade Bioscience, Pacific Marine Biotech, GT Medical, Kiyatec, Novocure, IN8Bio, and Servier, providing patients access to trials for glioblastoma, PCNSL, and other brain cancers. The organization also advocates for policy changes through the Promising Pathway Act initiative.

Differentiator

Problem solved

Functional benefit

Products and services

• Direct Connect Program A direct patient navigation service that connects brain cancer patients to brain tumor specialists, neurosurgeons, neuro-oncologists, brain cancer centers, clinical trials, and advanced treatments through a 5-step intake process including personal connection, hope assurance, needs assessment, Patient Empowerment Plan development, and facilitated connection to care. Free to patients and caregivers.
• EBCI Mobile App A mobile application available on iOS and Android providing brain cancer patients and caregivers with 24/7 access to clinical trial previews, patient resources, research links, important articles, meetings and events, calls to action, donation capabilities, and bookstore access.
• Patient Resource Center Comprehensive educational materials including fact sheets, videos, and guides covering immunotherapy side effects, cancer care questions, clinical trial considerations, Medicare coverage, medical terminology, and treatment options for brain tumor patients.
• Caregiver Resource Center Resources for caregivers including the Caregiver's Creed, web resources on family caregiving, mental health support, financial and legal guidance, technology for caregivers, and legacy projects.
• Health Insurance Navigator/Advocate Service helping brain cancer patients navigate health insurance, understand coverage options, and access needed treatments and clinical trials through dedicated advocacy staff.
• Travel and Financial Resources Connection to transportation services including non-emergency medical flights, ambulance rides, and local travel assistance through partnerships with Patient AirLift Services (PALS - Skyhope), Travel To Hope, Medical Travel Programs, and American Cancer Society Road To Recovery.
• Pediatric Brain Cancer Resources Specialized resources for pediatric brain tumors including information on tumor types (medulloblastoma, astrocytomas, DIPG, etc.), clinical trial information, and links to pediatric cancer centers and support organizations.

Quantifiable outcome

• 60% of patients and 58.3% of care partners reported that information received from healthcare providers was insufficient, highlighting unmet needs EBCI addresses through its education programs

Named customers4 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

20 partnerships are on record, tiered core and minor.

• Belay DiagnosticscoreGTM or Marketing Partner · 29 January 2026EBCI partnered with Belay Diagnostics to promote awareness and patient access to Summit™ 2.0 Liquid Biopsy and Vantage™ Liquid Biopsy, diagnostic tools for molecular characterization of suspected CNS tumors based on research from Johns Hopkins University.
• Deciphera Pharmaceuticals Inc.coreGTM or Marketing PartnerCorporate sponsorship supporting EBCI's educational webinar on New Developments in PCNSL Treatment, featuring discussions on clinical trials including PROSPECT, EIFEL, and TakeAim.
• Great Purpose ProductionsminorGTM or Marketing PartnerCorporate sponsorship for educational video production and webinar content.
• NovocurecoreGTM or Marketing PartnerLong-standing partnership since 2007, with Novocure sponsoring caregiver self-care webinars and providing Optune Gio device education. Novocure develops tumor treating fields therapy for cancer treatment.
• ServiercoreGTM or Marketing PartnerPartnership to spread awareness of IDH1 and IDH2 markers. Servier's VORANIGO® (vorasidenib) is the first targeted therapy for Grade 2 IDH-mutant glioma.
• ImvaxcoreGTM or Marketing PartnerPartnership to help patients access Imvax's clinical study for newly diagnosed glioblastoma. Imvax is developing IGV-001, a personalized whole tumor-derived immunotherapy using the Goldspire™ platform.
• Exvade BiosciencecoreGTM or Marketing PartnerPartnership to raise awareness of Exvade's groundbreaking Tumor Monorail Device clinical trial at Duke University for recurrent glioblastoma treatment.
• Pacific Marine BiotechcoreGTM or Marketing PartnerPartnership for glioblastoma brain cancer trial of Immune12, a marine-derived therapeutic. Phase 2 clinical trial recruiting patients in Australia.
• GT Medical TechnologiescoreGTM or Marketing PartnerPartnership for GammaTile Therapy patient education collaboration. GammaTile is a radiation treatment specifically designed for use inside the brain.
• IN8BiocoreGTM or Marketing PartnerPartnership to help patients access IN8bio's gamma-delta T cell therapy clinical trial for glioblastoma treatment.
• KiyateccoreGTM or Marketing PartnerPartnership promoting awareness of Kiyatec's 3D Predict™ test for personalizing cancer treatment using ex vivo 3D cell culture technology.
• CuriscoreGTM or Marketing PartnerPartnership to pre-qualify patients for PCNSL TakeAim Lymphoma Clinical Trial evaluating emavusertib (CA-4948), an oral IRAK4 inhibitor.
• ONO PharmaceuticalcoreGTM or Marketing PartnerCorporate partner supporting PCNSL patient education initiatives. ONO's tirabrutinib was approved in Japan for relapsed or refractory PCNSL.
• NX Development CorpcoreGTM or Marketing PartnerPartnership for Gleolan® patient education, an FDA-approved optical imaging agent that helps neurosurgeons visualize brain tumors during surgery.
• Jazz PharmaceuticalsminorGTM or Marketing PartnerCorporate partner supporting EBCI's patient education and advocacy initiatives.
• Telix PharmaceuticalsminorGTM or Marketing PartnerCorporate partner supporting EBCI's educational and outreach programs.
• ChimerixminorGTM or Marketing PartnerCorporate partner supporting EBCI's patient advocacy and education initiatives.
• Nuvation BiominorGTM or Marketing PartnerCorporate partner supporting EBCI's patient education and advocacy programs.
• National Cancer Institute (NCI)coreStrategic or Co-development PartnerPartnership for advocacy, education, and placement into clinical trials for brain cancer patients through NCI-CONNECT program.
• ASCOcoreStrategic or Co-development PartnerPartnership to boost patient education, access, and clinical trial participation through collaboration with American Society of Clinical Oncology.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• National Brain Tumor Society: Largest U.S. non-profit dedicated to brain tumor advocacy, research funding, and policy. Directly comparable as a disease-specific patient advocacy non-profit competing for the same donor, sponsor, and patient communities in brain cancer.
• American Brain Tumor Association: Long-standing U.S. non-profit providing brain tumor patient education, support services, and research funding. Closely comparable to EBCI in mission, patient-services model, and donor base.
• Musella Foundation for Brain Tumor Research: Patient-focused non-profit funding brain tumor clinical trials and operating VirtualTrials.org, a clinical trial matching database. Comparable to EBCI's Direct Connect clinical-trial-pre-qualification mission.
• Pediatric Brain Tumor Foundation: Non-profit focused specifically on pediatric brain tumors, combining research funding, family support, and advocacy. Comparable to EBCI's pediatric brain cancer resource vertical.
• Cancer Support Community: National non-profit providing psychosocial support, education, and navigation services to cancer patients and caregivers. Comparable to EBCI in service model (navigation, education, caregiver support) even though not disease-specific.

Broad incumbents

• American Cancer Society: Largest U.S. cancer non-profit with broad patient support, research, and advocacy programs. Competes for the same donor dollars and has substantially larger infrastructure; functions as the broad incumbent in patient navigation and policy advocacy.
• Livestrong Foundation: National non-profit providing cancer survivor navigation, financial support, and advocacy. Comparable as a broad patient-services and advocacy non-profit in the cancer space.

Emerging players

• CLL Society: Disease-specific patient advocacy non-profit focused on chronic lymphocytic leukemia, offering patient education, clinical trial matching, and expert medical advisory content. Comparable to EBCI in the disease-specific patient-advocacy business model.
• Imerman Angels: Non-profit providing one-on-one peer mentor connections for cancer patients and caregivers. Comparable to EBCI's caregiver support and patient-to-specialist connection model.

Others

• National Cancer Institute: U.S. federal agency and EBCI's partner through the NCI-CONNECT program. Not a competitor but a strategic comparator for clinical-trial patient-placement infrastructure and authoritative patient education content.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/endbraincancer
• YouTubeyoutube.com/@EndBrainCancer
• Facebookfacebook.com/EndBrainCancer
• LinkedInlinkedin.com/company/chris-elliott-fund
• Instagraminstagram.com/endbraincancer

Revenue estimate

Valuation estimate

Number of profiles

Profiles19 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about End Brain Cancer